orphan drug designation – Page 2 – Discover Pharma

Welcome to Discover Pharma! Today is : October 28, 2026

orphan drug designation

Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
Cereno taps global CRO for next big step in pulmonary hypertension drug trial
Selection of CRO marks key milestone in advancing CS1 as [...]

May 5, 2026
Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
Eleva doses first volunteers with new therapy targeting rare kidney disease
Dosing of CPV-104 in healthy volunteers marks key milestone in [...]

May 5, 2026
Advanced Therapies,Clinical & Regulatory,Opinion & Events
Poolbeg receives FDA Orphan Drug Designation for POLB 001
Poolbeg Pharma has been granted Orphan Drug Designation (ODD) by [...]

May 5, 2026
Clinical & Regulatory,Drug Discovery & Development
Kaerus receives dual FDA designations for lead Fragile X candidate
Kaerus Bioscience has been granted Orphan Drug Designation and Rare [...]

May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK